Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J. Pivot X, et al. Among authors: lortholary a. Clin Breast Cancer. 2023 Oct;23(7):e412-e419. doi: 10.1016/j.clbc.2023.06.007. Epub 2023 Jun 20. Clin Breast Cancer. 2023. PMID: 37423801
Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial.
Pivot X, Lortholary A, Abadie-Lacourtoisie S, Mefti-Lacheraf F, Pujade-Lauraine E, Lefeuvre C, Letessier S, Morvan P, Dür C, Frimat L. Pivot X, et al. Among authors: lortholary a. Breast. 2011 Dec;20(6):510-4. doi: 10.1016/j.breast.2011.05.006. Epub 2011 Jul 2. Breast. 2011. PMID: 21727006 Free article. Clinical Trial.
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Hardy-Bessard AC, Delva R, Pivot X, Espié M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY. Hardy-Bessard AC, et al. Among authors: lortholary a. Bull Cancer. 2012 Jun;99(6):609-18. doi: 10.1684/bdc.2012.1586. Bull Cancer. 2012. PMID: 22665515 Free article. Clinical Trial. French.
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators. Pivot X, et al. Among authors: lortholary a. Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0. Epub 2013 Jun 11. Lancet Oncol. 2013. PMID: 23764181 Clinical Trial.
[Breast cancer screening: On our way to the future].
Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG). Delaloge S, et al. Among authors: lortholary a. Bull Cancer. 2016 Sep;103(9):753-63. doi: 10.1016/j.bulcan.2016.06.005. Epub 2016 Jul 26. Bull Cancer. 2016. PMID: 27473920 Review. French.
[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]].
Delaloge S, Bachelot T, Bidard FC, Espie M, Brain E, Bonnefoi H, Gligorov J, Dalenc F, Hardy-Bessard AC, Azria D, Jacquin JP, Lemonnier J, Jacot W, Goncalves A, Coutant C, Ganem G, Petit T, Penault-Llorca F, Debled M, Campone M, Levy C, Coudert B, Lortholary A, Venat-Bouvet L, Grenier J, Bourgeois H, Asselain B, Arvis J, Castro M, Tardivon A, Cox DG, Arveux P, Balleyguier C, André F, Rouzier R; Intergroupe national de recherche sur le cancer du sein Unicancer (UCBG). Delaloge S, et al. Among authors: lortholary a. Bull Cancer. 2016 Nov;103(11):951-952. doi: 10.1016/j.bulcan.2016.10.009. Epub 2016 Oct 28. Bull Cancer. 2016. PMID: 28029350 French. No abstract available.
Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L, Fricker JP, Nogues C, Mouret-Fourme E, Stoppa-Lyonnet D, Caron O, Lortholary A, Faivre L, Lasset C, Mari V, Gesta P, Gladieff L, Hamimi A, Petit T, Velten M. Bignon L, et al. Among authors: lortholary a. Breast J. 2018 May;24(3):269-277. doi: 10.1111/tbj.12887. Epub 2017 Sep 19. Breast J. 2018. PMID: 28929593 Clinical Trial.
Fluctuation of the left ventricular ejection fraction in patients with HER2-positive early breast cancer treated by 12 months of adjuvant trastuzumab.
Jacquinot Q, Paget-Bailly S, Fumoleau P, Romieu G, Pierga JY, Espié M, Lortholary A, Nabholtz JM, Mercier CF, Pauporté I, Henriques J, Pivot X. Jacquinot Q, et al. Among authors: lortholary a. Breast. 2018 Oct;41:1-7. doi: 10.1016/j.breast.2018.06.001. Epub 2018 Jun 15. Breast. 2018. PMID: 29913374 Clinical Trial.
196 results